CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 302 enrolled
Drug / intervention
Insulin Biphasic Aspart 30/70 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00393705
NCT00393705Phase 4Completed

A Comparison of Insulin Lispro MM Intensive Mixture Therapy With Progressive Dose-Titration of Insulin Lispro LM or Biphasic Insulin Aspart 30/70

Eli Lilly and Company·interventional·Posted Oct 30, 2006·Updated Jul 20, 2010

In Brief

A Phase 4 clinical trial evaluating Insulin Biphasic Aspart 30/70, insulin lispro LM, and 1 other intervention for Diabetes Mellitus, Type 2. Completed, enrolled 302 participants across 9 sites in 5 countries.

Detailed Summary

Investigation into patients with type 2 diabetes mellitus not achieving adequate glycemic control while treated with combination of premixed insulin analogue formulations twice daily and metformin will be randomly assigned to follow one of two insulin treatment strategies used in combination with metformin administration. The aim of the trial is to try to achieve optimal metabolic control and explore full therapeutic potential of the strategies, patients in both arms will follow progressive insulin dose titration algorithms for 16 weeks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCroatia, Poland, Romania, South Africa, Turkey (Türkiye)
Collaborators--

Timeline

Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 30, 2006
Enrollment StartOct 1, 2006
Primary CompletionMar 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 19.7 years ago

Interventions

Insulin Biphasic Aspart 30/70drug

Participant adjusted dose, twice daily, injected subcutaneously for 16 weeks

insulin lispro LMdrug

Participant adjusted dose, injected subcutaneously for 16 weeks - possibility of using instead of insulin lispro MM before evening meal if there is a risk of hypoglycemia after the dinner or high fasting glucose levels.

insulin lispro MMdrug

Participant adjusted dose, three times per day, injected subcutaneously for 16 weeks

insulin lispro LMdrug

Participant adjusted dose, twice daily, injected subcutaneously for 16 weeks